Development of mRNA-platform vaccines

mRNA平台疫苗的开发

基本信息

  • 批准号:
    10541207
  • 负责人:
  • 金额:
    $ 84.15万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-01-21 至 2025-12-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY Pertussis is a respiratory disease caused by the obligate human pathogen Bordetella pertussis. Two generations of pertussis vaccines have been developed and licensed: whole cell pertussis (DTP) and acellular pertussis (DTaP/Tdap). Pertussis was thought to be a disease of the past but has recently re-emerged. The number of cases of pertussis in 2012 was 48-fold over the lowest year on record (1976), which was also a 50-year high. While the increase of pertussis has multiple potential reasons, epidemiological studies clearly suggest that the duration of immunity of both DTaP and Tdap wanes quickly each year after a booster, and regresses to non- protective levels in humans. Each dose of whole cell vaccine contains hundreds of antigens, of which numerous are immunodominant. Whole cell vaccines also induce T helper 1 and 17 (Th1/Th17) cellular immune responses. On the other hand, acellular vaccines focus Th2-mediated humoral responses exclusively to pertussis toxin, filamentous hemagglutinin, pertactin, and fimbriae. We aim to develop a vaccine that would induce Th1 responses and include a greater number of antigens than acellular vaccines. mRNA vaccines provide a platform that can be easily modified for the targeted antigen/pathogen and they induce Th1 responses. mRNA vaccines encode the antigen, which once expressed, results in immunity mediated by Tfh responses. We used an mRNA platform to screen antigens of B. pertussis and identified a protective multivalent formulation (mRNA-DTP10; 8 pertussis antigens with diphtheria and tetanus antigens) in a murine challenge model. In this project, we will further extend our studies and investigate the correlates of protection of the mRNA-pertussis vaccine in the murine model with longevity studies and examine DTaP prime / mRNA-boost effects (SA1). Next, we will utilize the coughing rat model of pertussis with whole body plethysmography to compare mRNA, whole cell, and acellular immunity for protection against cough (SA2). We will study the mRNA pertussis vaccine in immunogenicity and challenge experiments using the baboon model of pertussis (SA3). Lastly, we will aim to develop a suite of assays to phenotype antibodies produced by mRNA pertussis vaccines and bridge each of the pertussis models, which will facilitate clinical development. Through these studies, we aim to characterize the mRNA-pertussis immunity and develop a clearer understanding of how this vaccine platform can be used to overcome “complex or difficult” pathogens that employ numerous virulence factors. We expect the data acquired in each aim will result in a deeper understanding of pertussis immunity as well as illuminate the mRNA platform for bacterial vaccines.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Fredrick Heath Damron其他文献

Fredrick Heath Damron的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Fredrick Heath Damron', 18)}}的其他基金

13th International Bordetella Symposium
第13届国际博德特氏菌研讨会
  • 批准号:
    10506485
  • 财政年份:
    2022
  • 资助金额:
    $ 84.15万
  • 项目类别:
International Bordetella Symposia
国际博德特氏菌研讨会
  • 批准号:
    10469207
  • 财政年份:
    2022
  • 资助金额:
    $ 84.15万
  • 项目类别:
Development of mRNA-platform vaccines
mRNA平台疫苗的开发
  • 批准号:
    10211558
  • 财政年份:
    2021
  • 资助金额:
    $ 84.15万
  • 项目类别:
Development of mRNA-platform vaccines
mRNA平台疫苗的开发
  • 批准号:
    10331084
  • 财政年份:
    2021
  • 资助金额:
    $ 84.15万
  • 项目类别:
Development of mucosal vaccines to protect against pertussis
开发预防百日咳的粘膜疫苗
  • 批准号:
    10333333
  • 财政年份:
    2019
  • 资助金额:
    $ 84.15万
  • 项目类别:
Development of mucosal vaccines to protect against pertussis
开发预防百日咳的粘膜疫苗
  • 批准号:
    10548222
  • 财政年份:
    2019
  • 资助金额:
    $ 84.15万
  • 项目类别:
Development of mucosal vaccines to protect against pertussis
开发预防百日咳的粘膜疫苗
  • 批准号:
    10084257
  • 财政年份:
    2019
  • 资助金额:
    $ 84.15万
  • 项目类别:

相似海外基金

Are acellular vaccines driving the rise of pertactin-deficient Bordetella pertussis
无细胞疫苗是否会导致缺乏百日咳博德特氏菌的增加
  • 批准号:
    10364771
  • 财政年份:
    2021
  • 资助金额:
    $ 84.15万
  • 项目类别:
Outer Membrane Proteins of Francisella tularensis as Acellular Vaccines
土拉弗朗西斯菌外膜蛋白作为无细胞疫苗
  • 批准号:
    8377059
  • 财政年份:
    2012
  • 资助金额:
    $ 84.15万
  • 项目类别:
Outer Membrane Proteins of Francisella tularensis as Acellular Vaccines
土拉弗朗西斯菌外膜蛋白作为无细胞疫苗
  • 批准号:
    8233019
  • 财政年份:
    2011
  • 资助金额:
    $ 84.15万
  • 项目类别:
Outer Membrane Proteins of Francisella tularensis as Acellular Vaccines
土拉弗朗西斯菌外膜蛋白作为无细胞疫苗
  • 批准号:
    7676562
  • 财政年份:
    2009
  • 资助金额:
    $ 84.15万
  • 项目类别:
Acellular vaccines against Francisella tularensis
土拉弗朗西斯菌无细胞疫苗
  • 批准号:
    6358571
  • 财政年份:
    2001
  • 资助金额:
    $ 84.15万
  • 项目类别:
Acellular vaccines against Francisella tularensis
土拉弗朗西斯菌无细胞疫苗
  • 批准号:
    6736353
  • 财政年份:
    2001
  • 资助金额:
    $ 84.15万
  • 项目类别:
Acellular vaccines against Francisella tularensis
土拉弗朗西斯菌无细胞疫苗
  • 批准号:
    6511518
  • 财政年份:
    2001
  • 资助金额:
    $ 84.15万
  • 项目类别:
Acellular vaccines against Francisella tularensis
土拉弗朗西斯菌无细胞疫苗
  • 批准号:
    6632433
  • 财政年份:
    2001
  • 资助金额:
    $ 84.15万
  • 项目类别:
Acellular vaccines against Francisella tularensis
土拉弗朗西斯菌无细胞疫苗
  • 批准号:
    6885778
  • 财政年份:
    2001
  • 资助金额:
    $ 84.15万
  • 项目类别:
ACELLULAR VACCINES AGAINST BACTERIAL PATHOGENS
针对细菌病原体的无细胞疫苗
  • 批准号:
    3071049
  • 财政年份:
    1992
  • 资助金额:
    $ 84.15万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了